Clearside Biomedical Inc expected to post a loss of 13 cents a share - Earnings Preview

Clearside Biomedical,

10/08/2024 01:03

* Clearside Biomedical Inc  CLSD.OQ   CLSD.O  is expected
to show
a fall in quarterly revenue when it reports  results on August
12 for the period ending June 30 2024
    * The Alpharetta Georgia-based  company is expected to
report a
85.1% decrease in revenue to $152 thousand from $1.02 million a
year ago, according to the mean estimate from 5 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Clearside Biomedical Inc
is
for a loss of 13 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Clearside
Biomedical Inc is $5.00​, above​ its last closing price
of $1.09. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.14       -0.14      -0.15     Missed  -9
 Dec. 31 2024  -0.08       -0.09      -0.08     Beat    8.6
 Jan. 1 0001   -0.16       -0.15      -0.15     Met     3.2​
 Jun. 30 2023  -0.14       -0.14      -0.15     Missed  -5.9
 ​​Mar.        -0.14       -0.14      -0.15     Missed  -7.1
 31 2023                                                
 Dec. 31 2022  -0.13       -0.13      -0.16     Missed  -27​
 Sep. 30 2022  -0.05       -0.03      -0.13     Missed  -282.4
 Jan. 1 0001   -0.13       -0.13      -0.13     Met     1.5
 This summary was machine generated August 10 at 00:03 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)